Amgen’s Aranesp Meets Primary Endpoints in Phase 3

Amgen’s Aranesp soared in a Phase 3 trial, meeting its primary endpoint of reducing the incidence of red blood cell transfusions in anemic patients with low and intermediate-1 risk myelodysplastic syndrome.

Aranesp is indicated for the treatment of anemia due to chronic kidney disease and for patients with nonmyeloid malignancies whose anemia is due to concomitant myelosuppressive chemotherapy and at least two more months of treatment is needed.